• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.2220 -0.0068 (-2.97%)
Delayed Quote Updated: 3:59 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,920,181
Open 0.2290
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2288
Today's Range 0.2213 - 0.2400
52wk Range 0.1829 - 0.3970
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
November 17, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
November 12, 2026
From CytoDyn Inc.
Via GlobeNewswire

Performance

52-Week Range 44.1% below 52-week high
0.2220
0.1852W Low 0.4052W High
1 Week 17.0% below 1-week high
0.221W Low 0.271W High

Cytodyn Inc (CYDY) traded between $0.18 and $0.40 over the past 52 weeks and last traded at $0.22, 44.1% below its 52-week high. Over the past week it ranged between $0.22 and $0.27.

Past 12 Months
-11.3%
-9.4%
+5.7%
-34.5%
-17.8%
-26.0%
1W -$0.03
1M -$0.02
3M +$0.01
6M -$0.12
YTD -$0.05
1Y -$0.08

CYDY was -26.0% over the past year, -34.5% over six months, -17.8% year to date, -11.3% in the last week.

12 Months vs Market
CYDY
-26.0%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months CYDY returned -26.0% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.98× 3-mo avg
Today 1,920,181 3-mo avg 2.0M
1W
2.7M
1M
2.1M
3M
2.0M
6M
1.9M
YTD
1.9M
1Y
1.9M

CYDY most recently traded 1,920,181 shares against a 3-month average daily volume of 2.0M.

More News

Read More
News headline image
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
November 10, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
October 26, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO ↗
October 19, 2026
Via MarketBeat
News headline image
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
October 19, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Host Investor Webcast
October 15, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
October 08, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer ↗
September 19, 2026
Via MarketBeat
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
September 18, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
September 15, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced
September 14, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
September 01, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease
June 11, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
June 04, 2026
From Natera, Inc.
Via Business Wire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
CytoDyn to Present at the LD Micro Invitational XVI
May 15, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From BioMedWire
Via GlobeNewswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
From BioMedWire
Via GlobeNewswire
News headline image
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
April 27, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn to Host Investor Webcast
April 23, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
April 22, 2026
From CytoDyn Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cytodyn Inc publicly traded?
Yes, Cytodyn Inc is publicly traded.
What exchange does Cytodyn Inc trade on?
Cytodyn Inc trades on the OTC Traded
What is the ticker symbol for Cytodyn Inc?
The ticker symbol for Cytodyn Inc is CYDY on the OTC Traded
What is the current price of Cytodyn Inc?
The current price of Cytodyn Inc is 0.2220
When was Cytodyn Inc last traded?
The last trade of Cytodyn Inc was at 11/20/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap